Core Viewpoint - Changfeng Pharmaceutical (02652) has submitted a filing application to the China Securities Regulatory Commission (CSRC) regarding the proposed implementation of full circulation of H-shares, converting approximately 107.4 million unlisted domestic shares into H-shares on a one-to-one basis [1] Group 1 - The company plans to convert approximately 107.4 million unlisted shares into H-shares, which will then be listed and traded on the Hong Kong Stock Exchange [1] - The conversion is contingent upon completing all regulatory requirements, including filing with the CSRC and obtaining necessary approvals from the Hong Kong Stock Exchange [1] - Upon completion, the 107.4 million unlisted shares will be converted into an equal number of H-shares [1]
长风药业就建议实施H股全流通向中国证监会备案